The objective of this study was to analyze and collate data available on immunologic detection of HIV specific antibodies in the urine of patients infected with HIV. Serologic immunoassays with slight or no modification were employed to detect HIV antibodies in the urine. Paired urine and sera specimens from the same patient were used for the detection of HIV-1 antibodies both in urine and serum. Urinary immunoassays detected HIV-1 antibodies with 98.8 -100 % sensitivity and 99.2 -100% specificity. These immunoassays could effectively detect HIV-1 IgA antibody as well as HIV-1 group-O antibody. The occurrence of HIV-1 IgA antibodies in urine was significantly higher in all high risk subjects and was frequently found in the urine of seronegative partners. The combined use of urine and serum immunoassays detected a higher frequency of HIV-1 antibody -positive cases than either assay alone. Immunoassays for the detection of HIV-1 antibodies in urine are accurate, meet the regulatory criteria and may be highly valuable in mass screening, epidemiologic studies, blood banking and other situations where blood collection is impractical. Further urine collection is simple, economic, user friendly and free of occupational HIV infection and pain.
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Identification of Tuberculosis Biomarkers via Native Antigen Array Profiling
John T. Belisle Department of Microbiology, Immunology and Pathology, Colorodo State University, Colorodo, USA.
Tuberculosis control requires early and sensitive diagnosis of infection and disease. Recently our laboratory showed that different stages of disease were distinguishable via 2-D Western blot analyses of Mycobacterium tuberculosis culture filtrate proteins. This methodology, however, does not allow for high-throughput testing and suitable reproducibility with multiple sera is not easily obtained. Advances in protein microarray technology provide a realistic mechanism to screen a large number of serum samples against thousands of proteins to identify biomarkers of disease states. Techniques were established for separation of native M. tuberculosis cytosolic and culture filtrate proteins, resulting in 960 unique protein fractions that were used to generate protein microarrays. Evaluation of serological reactivity from 42 patients in three tuberculosis disease states and healthy PPD+ individuals demonstrated that HIV negative cavitary-and noncavitary-TB patients recognized 126 and 59 fractions, respectively. Sera from HIV patients coinfected with TB recognized 20 fractions, of which five overlapped with those recognized by non-HIV TB patients and 15 were unique to the HIV+TB+ disease state. Identification of antigens within the reactive fractions yielded eleven products recognized by both cavitary-and noncavitary-TB patients, and four proteins (HspX, MPT64, PstS1, and TrxC) specific to cavitary-TB patients. Moreover, four novel B cell antigens (BfrB, LppZ, SodC, and TrxC) of human tuberculosis were identified. These novel antigens were obtained in a purified form and tested against TB patients sera. Additionally, the post-translational glycosylation of one of these proteins was defined and the role of glycoslyation in serological recognition evaluated. Finally, these studies as well as the evaluation in serological recognition evaluated. Finally, these studies as well as the evaluation of commonly used products such as the A60 antigen reveal that lipoarabinomannan is the most strongly recognized of the M. tuberculosis serological antigens. Thus, it now appears a major effort should be made with state-of-the art techniques to address issues of poor specificity associated with lipoarabinomannan as a serological marker.
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Microarray Technology in The Analysis of the Cencer Genome.
John K Cowell
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York.
Expression and copy number arrays have been used extensively in defining the cancer genome and have been used in predicting prognosis and diagnosis, stratifying patients for clinical trials and discovery of novel cancer genes. Array comparative genome hybridization (aCGH) identifies losses, gains and amplifications in cancer cells. Amplifications in breast cancer involving HER2, in neuroblastoma involving NMYC and in gliomas involving EGFR have important implications for clinical management of these patients and are accurately and quickly identified using aCGH. Prognostic indicators that we have developed involve the Ip loss/19q gain in anaplastic oligodendrogliomas which predicts response to standard chemotherapy, and gain of Iq in medulloblastomas has been shown to be a univariate predictor of overall survival for this cancer. aCGH also identifies consistent deletions in cancer cells, which with the recently developed 500K SNP mapping arrays, provides high resolution of the breakpoints associated with structural chromosome abnormalities. This high resolution when combined with gene expression array analysis identifies the driver genes for the abnormality and we have developed a computational tool to overlay CGH and gene expression data to streamline this analysis. Using this approach small deletions in 11 p15 in medulloblastomas identified USP47, RIG, DKK3 and MICAL2 as the only significantly downregulated genes in the deleted region. In gliomas homozygous deletion in 15q24 identified only WDR73 and PDE5A as candidate tumor suppressor genes. Analysis of heterozygous and homozygous deletions in 2p11 in acute lymphoblastic leukemia from Downs syndrome patients identified loss of the IGKV gene as important in the development of this leukemia, but interestingly this 2p11 region was not involved in acute megakaryoblastic leukemias from Downs syndrome patients. The high resolution characterization of chromosome translocation breakpoints is also a feature of aCGH arrays and in the analysis of the iso(17q) abnormality seen in medulloblastomas, multiple breakpoints were identified suggesting it is the gain of 17q that is the important consequence of this abnormality rather than disruption of a gene associated with the breakpoint. The combination of copy number change analysis and loss of heterozygosity analysis using the 500K mapping arrays allows an even more comprehensive analysis of the genetic events that have occurred in tumorigenesis and, in combination, can be used to predict ploidy in tumors which has important implications for the exposure of tumor suppressor genes. With the development of single platform, total genome analysis it is now possible to introduce combined aCGH and gene expression studies into Pathology Departments to facilitate the clinical management of patients with cancer.
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